Welcome to the e-CCO Library!

P358: Ustekinumab is effective for the treatment of chronic antibiotic-refractory pouchitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. E. Ollech*1, L. Glick1, R. Weisshof1, A. Israel1, K. El Jurdi1, N. Krugliak Cleveland1, R. D. Cohen1, S. R. Dalal1, D. T. Rubin1

Created: Friday, 22 February 2019, 9:41 AM
P359 Platelet-rich stroma injection (PRS) as a novel surgical treatment of refractory perianal fistulas in Crohn’s disease: A pilot study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Arkenbosch1, O. van Ruler2, R.S. Dwarkasing3, W.R. Schouten2, A.C. de Vries1, E.J.R. de Graaf2, C.J. van der Woude1

Created: Thursday, 30 January 2020, 10:12 AM
P359: A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Rowley1*, M. Taylor1, A. Duggal1, M. Foster1, S. Sirohi1, Y. Solanke1, C. Walshe1, M. Fyfe1, S. Webber1, S. Travis2

Created: Thursday, 21 February 2019, 9:14 AM
P359: Budesonide MMX in paediatric ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Meglicka*1, M. Dadalski1, A. Adamczuk1, J. Kierkus1

Created: Friday, 22 February 2019, 9:41 AM
P359: Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ghosh S.*1, Peyrin-Biroulet L.2, Sensky T.3, Casellas F.4, O'Shea C.5, Pappalardo B.6

Created: Wednesday, 20 February 2019, 10:36 AM
P359: Correlation of simple laboratory tests with clinical disease activity scores in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. Tayfur Yurekli, H. Koseoglu, M. Basaran, N.S. Buyukasik, a. Demirezer Bolat, F.E. Akin*, m. Tahtaci, e. Selvi, O. Ersoy

Created: Friday, 22 February 2019, 9:49 AM
P359: Evaluation of usability and performance of home fecal sampling using a dedicated device
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Solhaug, H.(1)*;Haukø, I.(2);Mørk, E.(1);
Created: Friday, 14 July 2023, 11:05 AM
P359: Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection
Year: 2021
Source: ECCO'21 Virtual
Authors: Knyazev, O.(1,2,3);Kagramanova, A.(4);Lishchinskaya, A.(1);Noskova, K.(5);Chernova, M.(6);Shkurko, T.(3);Veselov, A.(3);Kulakov, D.(1);Li, I.(1);Parfenov, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P359: Radiomics could predict surgery at 10 years in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Laterza, L.(1);Boldrini, L.(2);Tran, H.E.(2);Votta, C.(2);Larosa, L.(2);Minordi, L.M.(2);Scaldaferri, F.(1);Papa, A.(1);Armuzzi, A.(1);Gasbarrini, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Mazza1, A. Fascì1, V. Casini2, C. Ricci3, F. Munari3, L. Pirola4, C. Girelli5, G. Lupinacci6, L. Pastorelli7, F. Cavallaro7, N. Piazza O’Sed7, L. Ferraris8, A. Colucci8, A. Amato9, V. Maurizio1,10, G. Fiorino11, F. Caprioli1,10

Created: Thursday, 30 January 2020, 10:12 AM
P360: A randomised, assessor-blinded, multicentre trial comparing the efficacy, safety, and tolerability of a new tailored dosing regimen to day-before dosing regimen of colon cleansing agent used before colonoscopy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Kiesslich*1, C. Angelin2, K. Raymond2, W. Man A Hing3, J. Masure3, M. Stoltenberg2

Created: Friday, 22 February 2019, 9:49 AM
P360: Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Marrero Torres, R.(1);Coste-Sibilia, S.(1);Nieves-Jimenez, H.(1);Torres, G.(1);Rivera, E.(2);Torres, E.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Harpaz1,2, S. Ballentine1, B. E. Sands2, J-F. Colombel2, H. M. Ko*1,2

Created: Friday, 22 February 2019, 9:41 AM
P360: Role of intestinal ultrasound scores in the diagnosis of post-operative recurrence in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Amor Costa, C.(1)*;Suárez Ferrer , C.(1);Poza Cordón, J.(1);Yebra Carmona , J.(1);Rueda García , J.L.(1);Sánchez Azofra , M.(1);Martín Arranz, E.(1);González Díaz, I.(1);Amiama Roig, C.(1);Martín Arranz, M.D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P360: The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Mitrovic, M.(1);Jeremić, M.(2);Zlatković, D.(1);Pantelić, M.(1);Vrinić-Kalem, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P360: Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Claire P.*1, Severine B.2, Nicolas D.3, Maria N.4, Pierre D.4, Julien B.4, Romain G.4, Medina B.4, Myriam L.2, Benjamin P.4

Created: Wednesday, 20 February 2019, 10:36 AM
P360: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, M. Peters2, C. Hinds3, A. Kormilitzin4, V. Sexton5, P. Seeva1, O. Brain1, S. Keshav1, H. Uhlig1, A. Simmons6, J. Geddes5, G. Goodwin5, G. Collins7, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P361: Adherence to faecal calprotectin test in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Maréchal*1, I. Gastin2, C. Baumann2, B. Dirrenberger1, J.-L. Gueant2, L. Peyrin-Biroulet1

Created: Friday, 22 February 2019, 9:49 AM
P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Potapov*1, T. Radigina2, S. Petrichuk2, D. Gerasimova2, A. Illarionov1,3, A. Anushenko1, T. Erlikh-Fox4

Created: Friday, 22 February 2019, 9:41 AM